Journal
BIOMOLECULES
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/biom11020208
Keywords
anti-HIV; capsid; dipeptide mimic; in silico screening
Categories
Funding
- Japan Agency for Medical Research and Development (AMED) [18fk0410004h0503]
- JSPS KAKENHI [20H03362, 19K22488]
- AMED [JP20am0101098]
- Grants-in-Aid for Scientific Research [20H03362, 19K22488] Funding Source: KAKEN
Ask authors/readers for more resources
A small molecule designed to mimic hydrophobic interactions between HIV-1 capsid proteins has shown significant anti-HIV-1 activity. Structure activity relationship (SAR) studies of its derivatives provide valuable information for the design and development of novel anti-HIV agents targeting the capsid protein. This new drug has the potential to be an effective treatment for HIV in the future.
The capsid of human immunodeficiency virus type 1 (HIV-1) is a shell that encloses viral RNA and is highly conserved among many strains of the virus. It forms a conical structure by assembling oligomers of capsid (CA) proteins. CA dysfunction is expected to be an important target of suppression of HIV-1 replication, and it is important to understand a new mechanism that could lead to the CA dysfunction. A drug targeting CA however, has not been developed to date. Hydrophobic interactions between two CA molecules via Trp184/Met185 in CA were recently reported to be important for stabilization of the multimeric structure of CA. In the present study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site, was synthesized and its significant anti-HIV-1 activity was confirmed. Structure activity relationship (SAR) studies of its derivatives were performed and provided results that are expected to be useful in the future design and development of novel anti-HIV agents targeting CA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available